MeiraGTx is looking to march its Parkinson’s disease treatment forward into phase 3 after the gene therapy improved motor ability and quality of life in a small midphase trial. A total of 14 patients were given a one-time infusion of either a high or low dose of the therapy, dubbed AAV-GAD, whichdelivers a gene that codes for the enzyme that makes the neurotransmitter GABA. Source: Fierce Biotech 15/10/2024